Este informe ofrece un análisis detallado de los resultados en materia de sostenibilidad de 86 compañías europeas del sector Farmacéutico y de Biotecnología, basado en la evaluación de ESG Ratings de EthiFinance realizada en 2024 con datos correspondientes al ejercicio fiscal 2023. El estudio destaca las principales tendencias y conclusiones [...]
Our Chief Economist, Antonio Madera, shares his insights in the January 2025 Macro Bulletin, analyzing key economic trends and forecasts for the year ahead. • Geopolitical risks: Trump’s second term introduces trade and migration uncertainties; AI investments escalate the U.S.-China tech rivalry. • Global conflicts: The Israel-Hamas ceasefire offers temporary relief; [...]
Through this study EthiFinance provides an analysis of the ESG maturity of the industry, based on a review of public data from 60 asset managers in Spain. It also highlights the main emerging ESG trends that are gaining force in the industry, as impact investment, biodiversity and transition. Finally, the [...]
A través de este estudio EthiFinance proporciona un análisis de la madurez ESG de la industria, basado en una revisión de datos públicos de 60 gestoras de activos en España. También destaca las principales tendencias ESG emergentes que están cobrando fuerza en la industria, como la inversión de impacto, la [...]
This report provides a detailed analysis of the sustainability performance of 86 European companies in the Biotechnologies & Pharmaceuticals sector, based on EthiFinance’s ESG Ratings assessment conducted in 2024 with data reported for fiscal year 2023. The study highlights key trends and findings on the sector’s most material aspects across [...]
